[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE195553T1 - Kristallisierung von m-csf - Google Patents

Kristallisierung von m-csf

Info

Publication number
ATE195553T1
ATE195553T1 AT93915279T AT93915279T ATE195553T1 AT E195553 T1 ATE195553 T1 AT E195553T1 AT 93915279 T AT93915279 T AT 93915279T AT 93915279 T AT93915279 T AT 93915279T AT E195553 T1 ATE195553 T1 AT E195553T1
Authority
AT
Austria
Prior art keywords
csf
antagonists
directed
agonists
crystallization
Prior art date
Application number
AT93915279T
Other languages
English (en)
Inventor
Jayvardhan Pandit
Jarmila Jancarik
Sung-Hou Kim
Kirston Koths
Robert Halenbeck
Anna Lisa Fear
Eric Taylor
Ralph Yamamoto
Andrew Bohm
Original Assignee
Chiron Corp
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Univ California filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE195553T1 publication Critical patent/ATE195553T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93915279T 1992-06-09 1993-06-09 Kristallisierung von m-csf ATE195553T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09
PCT/US1993/005548 WO1993025687A1 (en) 1992-06-09 1993-06-09 Crystallization of m-csf

Publications (1)

Publication Number Publication Date
ATE195553T1 true ATE195553T1 (de) 2000-09-15

Family

ID=25406334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915279T ATE195553T1 (de) 1992-06-09 1993-06-09 Kristallisierung von m-csf

Country Status (7)

Country Link
US (2) US5866114A (de)
EP (2) EP0668914B1 (de)
JP (2) JPH08507916A (de)
AT (1) ATE195553T1 (de)
CA (1) CA2137793C (de)
DE (1) DE69329247T2 (de)
WO (1) WO1993025687A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1997033613A1 (en) * 1996-03-14 1997-09-18 Board Of Trustees Of The University Of Illinois Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
EP1772464B1 (de) 2001-02-09 2009-08-12 Genentech, Inc. Verfahren zur Identifizierung von indirekten IGF-1-Agonisten
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
HUP0400466A3 (en) 2001-07-11 2006-01-30 Maxygen Holdings Ltd Georgetow G-csf conjugates
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US20050124008A1 (en) * 2003-12-05 2005-06-09 Kauvar Lawrence M. Homogeneous competition assays
WO2005070447A2 (en) * 2004-01-21 2005-08-04 Chiron Corporation M-csf muteins and uses thereof
WO2006047505A2 (en) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Crystal structure of the c-fms kinase domain
DE602006020562D1 (de) 2005-06-01 2011-04-21 Maxygen Inc Hren dafür
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
WO2010062401A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
US8080246B2 (en) * 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
PL2510010T3 (pl) 2009-12-10 2016-05-31 Hoffmann La Roche Przeciwciała wiążące zewnątrzkomórkową domenę 4 ludzkiego CSF1R i ich zastosowanie
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
EP3943154A1 (de) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antikörper zur bindung von csf1r
WO2013036829A1 (en) 2011-09-09 2013-03-14 Genentech, Inc Treatment of th17 mediated inflammatory diseases
JP6242804B2 (ja) 2011-12-15 2017-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20140079699A1 (en) 2012-08-31 2014-03-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EA037561B1 (ru) 2014-06-23 2021-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
JP6920989B2 (ja) 2014-10-29 2021-08-18 ファイヴ プライム セラピューティクス インク がんのための併用療法
TW201630937A (zh) 2014-12-22 2016-09-01 戊瑞治療有限公司 用於治療ｐｖｎｓ之抗－ｃｓｆ１ｒ抗體
PT3283527T (pt) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc Terapêutica de combinação para o cancro
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
EP3558360A1 (de) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Behandlung von tumoren mit anti-csf-1r-antikörper in kombination mit einem anti-pd-l1-antikörper nach versagen einer anti-pd-l1/pd1-behandlung
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
US11421034B2 (en) 2017-09-13 2022-08-23 Five Prime Therapeutics, Inc. Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
ATE111921T1 (de) * 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
EP0506866B1 (de) * 1989-12-21 1993-10-20 Novo Nordisk A/S Verfahren zur kristallisation von enzymen
EP0586549B1 (de) * 1991-05-10 2000-09-20 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden

Also Published As

Publication number Publication date
JPH08507916A (ja) 1996-08-27
DE69329247T2 (de) 2001-05-31
WO1993025687A1 (en) 1993-12-23
CA2137793C (en) 2003-04-22
EP0668914B1 (de) 2000-08-16
EP0955365A3 (de) 2000-12-20
US5866114A (en) 1999-02-02
US6184354B1 (en) 2001-02-06
JP2004285076A (ja) 2004-10-14
EP0668914A1 (de) 1995-08-30
CA2137793A1 (en) 1993-12-23
DE69329247D1 (de) 2000-09-21
EP0955365A2 (de) 1999-11-10

Similar Documents

Publication Publication Date Title
ATE195553T1 (de) Kristallisierung von m-csf
PT86648A (pt) Method for the preparation of anti-retroviral compositions containing 3'-azido-2',3'-dideoxyuridine
ES2113368T3 (es) Antagonistas de serotonina.
IT8122675A0 (it) Mercaptoacil derivati di varie proline 4 sostituite e relative composizioni utili per il trattamento dell'ipertensione.
IT1222394B (it) Processo per la preparazione di 2,2,6,6 tetrametil 4 piperidilammine
NO920176D0 (no) Antagonister av gm-csf avledet fra karboksyterminalen
IT1217328B (it) Processo per la metallizzazione di materiali fibrosi
DE3851925D1 (de) Alkylaminalkoxyphenyl-Derivate, Verfahren zur Verwendung und sie enthaltende Zusammensetzungen.
DK0444853T3 (da) Hexahydrobenz(cd)indoler
ES2067541T3 (es) Mejoras en antagonistas de la serotonina y relacionadas con ellos.
IT8620796A0 (it) Processo per la preparazione dell'n-dimetilchitosano e suoi impieghi farmacologici.
ATE69220T1 (de) Sechsgliedrige heterocyclische derivate von n'substituiertenn,n'-diacylhydrazinen.
ATE63543T1 (de) 2-oxindolzwischenprodukte.
ES533939A0 (es) Un procedimiento de preparacion de nuevos derivados de 4-aminopiperidina
EP0480764A3 (en) Process to find stability of oil mixtures, including shale oil and fractions thereof
KR950700899A (ko) 히스타민 수용체 길항물질의 합성에 있어서 중간물질로써 유용한 4-피리딜과 4 피페리디닐아미다졸의 제조공정
IT1174473B (it) Procedimento per la produzione di polietelene di bassa densita'lineare
IT8621734A0 (it) Processo per la preparazione dell'alfa-n-[(ipoxatin-9-il)pentilossicarbonil-]arginina
DE59007354D1 (de) Monohydrochlorid und Monomethansulfonat von Amonafide.
DE69019301D1 (de) Herstellungsverfahren von Indolen.
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
CA1262906C (en) 3-(2-FUROYL)-5-ALCOXYCARBONYL-2,6-DIMETHYL-4-(2-NITROPHENYL)-1,4-DIHYDROPYRIDINES, CALCIUM ANTAGONISTS
NO891681D0 (no) Fremgangsmaate for syntese av c5+ hydrokarboner.
IT8719647A0 (it) Processo per la sintesi dell'epsiloncaprolattame.
FR2640414B1 (fr) Electro-aimant de coupure alimente en courant alternatif

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties